Visit other SMART + STRONG sites:
POZREAL HEALTHTU SALUD
Subscribe to:
E-newsletters
POZ magazine
POZ Personals
Sign In / Join
Username:
Password:

Back to home » Treatment News » Top Stories

Most Popular Stories
Life Expectancy With HIV Increases Dramatically
HIV Eradication: One Step Closer
Scientists Crack Integrase Inhibitor Mystery
Gilead Reports Success With Quad Pill and Boosting Drug
New Hope for HIV Eradication
Study: Demand for HIV Vaccine Will Depend on How Good It Is
What's That Mean?
(just double-click it!)

If you don't understand one of the words in this article, just double-click it. A window will open with a definition from mondofacto's On-line Medical Dictionary. If the double-click feature doesn't work in your browser, you can enter the word below:

Most Popular Lessons
The HIV Life Cycle
Shingles
Herpes Simplex Virus
Syphilis & Neurosyphilis
Treatments for Opportunistic Infections (OIs)
What is AIDS & HIV?
More News

Have medical or treatment news about HIV? Send press releases, news tips and other announcements to editors@aidsmeds.com.

Click here for more news


emailrssprint

January 28, 2008

Swiss Study Finds Less Lipodystrophy in Recent Years

People with HIV in Switzerland who started antiretroviral treatment after 2003 had less lipodystrophy—defined in this study as either fat loss in the face and limbs, fat gain in the trunk, or both—than those who started treatment between 2000 and 2002, say the authors of a new study published online by the British journal HIV Medicine. The authors credit a switch away from thymidine analogue drugs like Retrovir (zidovudine) and Zerit (stavudine) for much of the difference.

Researchers associated with the Swiss HIV Cohort Study examined the medical records of 6,016 Swiss HIV patients between 2000 and 2006. The researchers defined a new case of lipodystrophy as when a participant had rapid weight gain, rapid weight loss, accumulation of fat in the gut, or loss of fat in the limbs and face after starting HIV treatment.

At baseline, meaning the time of their first visit with a physician, 10 percent of participants already had fat loss, 10 percent had fat accumulation and 10 percent had both. Between 2003 and 2006, the use of Retrovir, Videx (didanosine) and Zerit decreased substantially. During the same period, use of Reyataz (atazanavir), tenofovir (found in Viread, Truvada and Atripla) and emtricitabine (found in Emtriva, Truvada and Atripla) increased substantially.

Over the course of the study, 10 percent of patients were diagnosed with only fat loss, 12.3 percent with only fat accumulation and 33 percent with either one or both measures. The percentage who developed lipodystrophy following HIV treatment initiation fell significantly between 2003 and 2006, and the percentage of people who changed or discontinued treatment because of lipodystrophy fell from 4 percent in 2003 to 1 percent in 2006.

The authors write, “We found that the probability of developing lipodystrophy had decreased [between 2003 and 2006], while the pattern of drug prescription had significantly changed.” They add, “While the use of thymidine analogues was almost universal in initial treatment in 2000, [Zerit] is no longer recommended in the guidelines for treatment initiation and had nearly disappeared by 2006, whereas [Retrovir] tends to be replaced by tenofovir.”

After controlling for a number of characteristics, researchers found that being older or black and having a high CD4 count were associated with more fat accumulation. Being older or female, having a high CD4 count or having taking abacavir (found in Ziagen, Epzicom and Trizivir) was associated with more fat loss. In previous studies, abacavir has been associated with gains in limb fat, and it should be noted that upon further analysis, the researchers of this study found that many people taking abacavir had switched to the drug after having taken another drug more commonly associated with limb fat loss.

Although certain drugs were associated with either fat accumulation—Viracept (nelfinavir) and abacavir—or fat loss—Viramune (nevirapine) and abacavir—the authors caution that association in this study does not mean that any of these drugs can be seen as the cause of the fat accumulation or loss.


Scroll down to comment on this story.

emailrssprint

Name:

(will display; 2-50 characters)

Email:

(will NOT display)

City:

(will display; optional)

Comment (500 characters left):

(Note: The AIDSmeds team review all comments before they are posted. Please do not include ":" "@" "<" ">" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

| Posting Rules

Previous Comments:

comments 1 - 4 (of 4 total)    

John Carter, San Diego, 2008-03-20 22:41:00
I got Buffalo Hump from meds or aids is there any way to get the hump down.

Jai, Ft. Lauderdale, 2008-01-30 13:19:56
Many of us are aware first hand of the side effects caused by these drugs mentioned. I would like to know if there are any drugs which may help reverse the lipodystrophy? And do it without any harmful side effects.

Mark Lewis, Aztec, New Mexico, 2008-01-29 23:39:05
The problem with this study is it only included people who had been in treatment for three years. Come back and repeat it after a decade and then we'll talk.

Hedge, Halifax, 2008-01-29 08:35:56
First the drug companys have to admit the drugs cause lipo as stated at the end of the article "the authors caution that association in this study does not mean that any of these drugs can be seen as the cause of the fat accumulation or loss." Denial is an amazing thing.

comments 1 - 4 (of 4 total)    


[Go to top]

Quick Links
AIDSmeds en Español
About HIV and AIDS
Lab Tests
My Cool Tools
HIV Meds
Starting Treatment
Switching Treatment
Drug Resistance
Side Effects
Disclosure
Lipodystrophy
Hepatitis & HIV
Women & Children
Fact Sheets
Treatment News
Community Forums
Blogs
Conference Coverage
Health Services Directory
POZ Magazine
Conference Coverage

17th Conference on Retroviruses and Opportunistic Infections (CROI 2010)
San Francisco, CA
February 16-19, 2010


5th IAS Conference on HIV Pathogenesis Treatment and Prevention (IAS 2009)
Cape Town, South Africa
July 19-22, 2009


16th Conference on Retroviruses and Opportunistic Infections (CROI 2009)
Montréal, Canada
February 8-11, 2009

more conference coverage


[ about AIDSmeds | AIDSmeds advisory board | our staff | advertising policy | advertise/contact us]
© 2010 Smart + Strong. All Rights Reserved. Terms of use and Your privacy